Private Capital Advisors Inc. acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to its most recent filing with the SEC. The firm acquired 17,771 shares of the biotechnology company’s stock, valued at approximately $599,000.

A number of other large investors have also added to or reduced their stakes in SRPT. Prentiss Smith & Co. Inc. raised its stake in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 3,166 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Sarepta Therapeutics by 54.2% in the first quarter. Nuveen Asset Management LLC now owns 28,589 shares of the biotechnology company’s stock valued at $846,000 after buying an additional 10,048 shares during the last quarter. Credit Suisse AG raised its stake in shares of Sarepta Therapeutics by 153.8% in the first quarter. Credit Suisse AG now owns 186,295 shares of the biotechnology company’s stock valued at $5,515,000 after buying an additional 112,899 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $2,395,000. Finally, AQR Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 25.5% in the first quarter. AQR Capital Management LLC now owns 52,367 shares of the biotechnology company’s stock valued at $1,550,000 after buying an additional 10,648 shares during the last quarter. Hedge funds and other institutional investors own 64.28% of the company’s stock.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded up 1.69% during trading on Friday, reaching $38.52. 1,499,963 shares of the company were exchanged. Sarepta Therapeutics, Inc. has a 52-week low of $23.51 and a 52-week high of $63.73. The firm has a 50-day moving average of $35.97 and a 200-day moving average of $32.56. The firm’s market cap is $2.12 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. The firm’s revenue for the quarter was up 350000.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.19) EPS. On average, equities analysts forecast that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current year.

WARNING: “17,771 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Private Capital Advisors Inc.” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/07/private-capital-advisors-inc-takes-position-in-sarepta-therapeutics-inc-nasdaqsrpt-updated-updated-updated.html.

Several equities research analysts have commented on the stock. Janney Montgomery Scott raised their price target on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a research note on Monday, July 24th. Morgan Stanley restated an “equal weight” rating and issued a $33.00 price target (up previously from $31.00) on shares of Sarepta Therapeutics in a research note on Thursday, July 20th. Robert W. Baird restated an “outperform” rating and issued a $96.00 price target (down previously from $102.00) on shares of Sarepta Therapeutics in a research note on Friday, July 21st. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 27th. Finally, Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Eight investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $61.28.

In other news, SVP Shamim Ruff sold 12,138 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Following the completion of the transaction, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Douglas S. Ingram bought 47,058 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the acquisition, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 78,056 shares of company stock valued at $3,224,208. Corporate insiders own 9.60% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.